Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: A therapeutic efficacy study

Malaria Journal

Volumn 15, Issue 1, 2016, Pages

  Tun, Kyaw Myo ^a,b   Jeeyapant, Atthanee ^c   Imwong, Mallika ^c   Thein, Min ^a   Aung, Sai Soe Moe ^a   Hlaing, Tin Maung ^a   Yuentrakul, Prayoon ^c   Promnarate, Cholrawee ^f   Dhorda, Mehul ^d,f   Woodrow, Charles J ^c,d   Dondorp, Arjen M ^c,d   Ashley, Elizabeth A ^c   Smithuis, Frank M ^b,d,e   White, Nicholas J ^c,d   Day, Nicholas P J ^c,d  

^a Department of Social Research Defence Services Medical Research Centre Tatkone Township   (Myanmar)

^b Myanmar Oxford Clinical Research Unit   (Myanmar)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Medical Action Myanmar   (Myanmar)

^f WorldWide Antimalarial Resistance Network   (Thailand)

Author keywords

Artemisinin resistance; Kelch 13 propeller; Myanmar; Parasite clearance half life; Plasmodium falciparum

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; PRIMAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; PROTOZOAL PROTEIN; QUINOLINE DERIVATIVE;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SMEAR; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE; GENE MUTATION; HALF LIFE TIME; HOSPITAL ADMISSION; HUMAN; K13 GENE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MYANMAR; NONHUMAN; OPEN STUDY; PARASITE CLEARANCE; PHENOTYPE; PROMOTER REGION; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; AGED; DRUG RESISTANCE; GENETICS; INFANT; MALARIA, FALCIPARUM; MIDDLE AGED; MISSENSE MUTATION; ORAL DRUG ADMINISTRATION; PARASITEMIA; PARASITOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYANMAR; PARASITEMIA; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS; QUINOLINES; YOUNG ADULT;

EID: 85007566185     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-016-1240-7     Document Type: Article

References (41)

1. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: A cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015; 15: 415-21.
2. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014; 371: 411-23.
3. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015; 211: 670-9.
4. Huang F, Takala-Harrison S, Jacob CG, Liu H, Sun X, Yang H, et al. A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis. 2015; 212: 1629-35.
5. Wang Z, Shrestha S, Li X, Miao J, Yuan L, Cabrera M, et al. Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007-2012. Malar J. 2015; 14: 168.
6. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014; 505: 50-5.
7. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: A clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010; 51: e82-9.
8. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361: 455-67.
9. Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015; 347: 428-31.
10. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci USA. 2013; 110: 240-5.
11. Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J. 2009; 8: 10.
12. Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006; 11: 1360-6.
13. Leang R, Barrette A, Bouth DM, Ménard D, Abdur R, Duong S, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008-2010. Antimicrob Agents Chemother. 2013; 57: 818-26.
14. Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: An observational cohort study. Lancet Infect Dis. 2015; 15: 683-91.
15. Saunders DL, Vanachayangkul P, Lon C. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med. 2014; 371: 484-5.
16. Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S, et al. Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother. 2015; 59: 4631-43.
17. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: An observational study. PLoS Med. 2013; 10: e1001398.
18. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: A longitudinal study. Lancet. 2012; 379: 1960-6.
19. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One. 2013; 8: e57689.
20. Wang Y, Yang Z, Yuan L, Zhou G, Parker D, Lee MC, et al. Clinical efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria at the China-Myanmar border. Am J Trop Med Hyg. 2015; 93: 577-83.
21. Huang F, Tang L, Yang H, Zhou S, Sun X, Liu H. Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China-Myanmar border. Malar J. 2012; 11: 278.
22. Wang Z, Wang Y, Cabrera M, Zhang Y, Gupta B, Wu Y, et al. Artemisinin resistance at the China-Myanmar border and association with mutations in the K13 propeller gene. Antimicrob Agents Chemother. 2015; 59: 6952-9.
23. WHO. Minutes of the drug resistance and containment Technical Expert Group. Geneva: World Health Organization; 2014.
24. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011; 10: 378.
25. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
26. Flegg JA, Guerin PJ, Nosten F, Ashley EA, Phyo AP, Dondorp AM, et al. Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. Malar J. 2013; 12: 411.
27. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
28. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011; 10: 339.
29. WHO. Status report on artemisinin and ACT resistance. Geneva: World Health Organization; 2015.
30. White LJ, Flegg JA, Phyo AP, Wiladpai-ngern JH, Bethell D, Plowe C, et al. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: A modelling approach. PLoS Med. 2015; 12: e1001823.
31. Worldwide Antimalarial Resistance Network. (WWARN). Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: An individual patient data meta-analysis. Malar J. 2015; 14: 359.
32. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet. 2015; 47: 226-34.
33. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, et al. A major genome region underlying artemisinin resistance in malaria. Science. 2012; 336: 79-82.
34. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010; 201: 570-9.
35. Anderson TJC, Nair S, McDew-White M, Cheeseman IH, Bilgic F, McGready R, et al. Anatomy of an ongoing soft selective sweep malaria parasites driven by artemisinin treatment. In: Society for molecular biology & evolution 2014 Meeting, 8-12 June 2014, Puerto Rico. Dublin: MCI Dublin; 2014. Abstract downloadable at https://mcidublin. conference-services. net/reports/template/onetextabstract. xml?xsl=template/onetextabstract. xsl&conferenceID=3958&abstractID=814496.
36. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: A parasite clearance rate study. Lancet Infect Dis. 2012; 12: 851-8.
37. Ye R, Hu D, Zhang Y, Huang Y, Sun X, Wang J, et al. Distinctive origin of artemisinin-resistant Plasmodium falciparum on the China-Myanmar border. Sci Rep. 2016; 6: 20100.
38. Feng J, Zhou D, Lin Y, Xiao H, Yan H, Xia Z. Amplification of pfmdr1, pfcrt, pvmdr1, and K13 propeller polymorphisms associated with Plasmodium falciparum and Plasmodium vivax isolates from the China-Myanmar border. Antimicrob Agents Chemother. 2015; 59: 2554-9.
39. Nyunt MH, Hlaing T, Oo HW, Tin-Oo LL, Phway HP, Wang B, et al. Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller, and a multidrug-resistance gene in the eastern and western border areas of Myanmar. Clin Infect Dis. 2015; 60: 1208-15.
40. Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015; 59: 4719-26.
41. Fairhurst RM. High antimalarial efficacy of dihydroartemisinin-piperaquine on the China-Myanmar border: the calm before the storm. Am J Trop Med Hyg. 2015; 93: 436-7.